Purpose: This study evaluated the clinical relevance of the dual-targeting strategy involving PI3K/AKT/mTOR and RAF/MEK/ERK pathways.
P
Experimental Design: We investigated safety, efficacy and correlations between tumor genetic alterations and clinical benefit in 236 patients with advanced cancers treated with phase I study drugs targeting PI3K and/or MAPK pathways in our Phase I Clinical Trials Program.
